Citations

Clear

4847 citation(s) found for "Yu, Eric".

BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy.
Hecht, J. Randolph , Patel, Sandip Pravin , Morelli, Maria Pia , Welling, Theodore H., Liechty, Kirstin B., Lozac’hmeur, Ariane, Beutner, Karl R., Ng, Eric Wai-Choi , Go, William Y., Maloney, David G. , Molina, Julian R. , Simeone, Diane M. , Kirtane, Kedar , Borad, Mitesh J. , Maus, Marcela V , Sunwoo, John B. , Lin, Yi , Garon, Edward B. , Kopetz, Scott , Locke, Frederick L.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS2676-TPS2676

10.1200/jco.2022.40.16_suppl.tps2676 Get It

TPS2676 Background: Solid tumors comprise > 90% of cancers. Metastatic colorectal cancer, non-small cell lung cancer, and pancreatic cancer are among the leading causes of cancer-related mortality (5-year overall survival: 14%, 6%, and 3%, respectively) (ACS. 2021). Chimeric antigen receptor (CAR) T-cell therapy has demonstrated clinical efficacy in hematologic malignancies (Neelapu S. et al. N Engl J Med. 2017). Translating engineered T-cell therapies to solid tumors has proven to be challenging due to a lack of tumor-specific targets that can discriminate cancer cells from normal cells. Previous studies using carcinoembryonic antigen (CEA) T-cell receptors and mesothelin (MSLN) CARs resulted in dose-limiting on-target, off-tumor toxicities (Parkhurst M, et al. Mol Ther. 2011; Tanyi J. Cellicon Valley '21). To create a therapeutic safety window, Tmod CAR T-cell therapy utilizes dual-signaling receptors to create a robust NOT logic gate capable of killing tumor cells, while leaving healthy cells intact (Hamburger A, et al. Mol Immunol. 2020). The 2 receptors in Tmod CAR T-cell therapy comprise an activator that recognizes an antigen on the surface of tumor cells that may also be present on normal cells, such as CEA and MSLN, and a blocker that recognizes a second surface antigen from an allele lost only in tumor cells. The frequency of HLA LOH among advanced GI solid tumor cancers in the Tempus real-world dataset is 16.3% with a range of 15.6%-20.8% between colorectal, pancreatic, and gastroesophageal tumors (Hecht R. et al. ASCO-GI 2022. Abstract #190). As such, HLA LOH offers a definitive tumor versus normal discriminator target for CAR T-cell therapy. Different activator/blocker combinations can be engineered with the Tmod platform technology and may be applied to T cells and natural killer cells in autologous and allogeneic settings. BASECAMP-1 is a currently enrolling observational study with key objectives of 1) To identify patients with somatic HLA LOH eligible for Tmod CAR T-cell therapy, and 2) To obtain leukapheresis and feasibility for the future EVEREST Tmod CAR T-cell trial. Methods: BASECAMP-1 (NCT04981119) patient eligibility has 2 parts: 1) Patients will be initially screened to identify germline HLA-A*02 heterozygosity by central NGS. If HLA-A*02 heterozygosity is confirmed, primary archival tumor tissue will be analyzed for somatic mutations by xT-Onco NGS testing. 2) If the tumor demonstrates HLA-A*02 LOH and the patient is eligible after screening, the patient will undergo leukapheresis. Banked T cells will be available for the autologous EVEREST Tmod CAR T-cell therapy interventional study to reduce waiting time at relapse. Clinical trial information: NCT04981119.
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).
Delord, Jean‐Pierre , Block, Matthew S. , Colón‐Otero, Gerardo , Jamet, Camille , Knutson, Keith L. , Lacoste, G, Tavernaro, Annette, Brandely-Talbot, Maud, Silvestre, Nathalie , Grellier, Benoît, Malone, Brandon, Onoue, Kousuke, Yamashita, Yoshiko, Quéméneur, Éric , Ottensmeier, Christian H. , Tourneau, Christophe Le , Lalanne, Ana Inés , Lantz, Olivier J , Knutson, Keith L. , Tanaka, Yuki , Bendjama, Kaidre

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 2637-2637

10.1200/jco.2022.40.16_suppl.2637 Get It

2637 Background: Mutation-associated neoantigens (MANAs) constitute attractive antigens for the design of cancer vaccines. However, clinical implementation remains challenging because of the patient specific nature of MANAs, hereby requiring that a bespoke vaccine is designed for each subject. We developed a pipeline for the genomic characterization and the design of tailored vaccine using a modified vaccinia Ankara viral vector. Methods: Immunogenicity, safety and early clinical activity of personalized cancer vaccines are being assessed in two phase I trials, respectively in high grade serous OC and HPV-negative HNSCC. Patients (Pts) at high risk of relapse are enrolled in the study being in remission following surgical primary treatment. High risk is defined as stage IIIC or IVA for OC and stage III or IVA for HNSCC. A vaccine is manufactured for each patient. OC pts are treated at asymptomatic relapse based on radiological finding or elevation of CA-125 with the vaccine alone; HNSCC pts in complete remission after surgery and adjuvant therapy are randomized to receive the vaccine either at the end of locoregional treatment or in combination with standard of care at relapse. The vaccine was administered weekly for 6 weeks and a booster dose every three weeks over a year or until progression, whichever occurred first. Results: At the time of the data cut-off, a total of 8 pts were treated: 4 relapsing OC pts, 3 HNSCC pts in complete remission and 1 relapsing HNSCC pt. AE attributable to the vaccine were mainly grade 1 injection site reactions and fatigue. One OC pt displayed an objective response 6 weeks after initiation of vaccine and for 9 months with a normalization of CA-125 until death from an unrelated cause; 1 other OC pt remains on treatment with a stable radiological disease for 11 months. The 2 other OC progressed at the first evaluation on day 43. HNSCC pts treated in complete remission received respectively 20, 15 and 4 doses, and remain on treatment and disease free. One HNSCC patient received 9 doses of vaccine after relapse in conjunction with chemotherapy and anti-PD-1 therapy and remains on treatment with stable disease after 5 months. Immune monitoring demonstrates priming of a polyepitopic T cell response against class I and II antigens. Responses were observed regardless of HLA and without cross-reactivity to the germline protein. Adaptive response was associated with a shift of CD4 and CD8 T cells toward an effector phenotype and innate cellular immunity was activated with a strong maturation and activation of NK cells. Immune changes were stronger in pts with controlled disease versus progressors. Conclusions: Data demonstrate that TG4050 is safe, well tolerated and able to induce T cell responses whatever the HLA haplotype. Early signs of clinical activity were observed in OC pt. These data pave the way for further development and synergistic immunotherapeutic combinations. Clinical trial information: NCT04183166.
Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102).
Mashru, Sandeep H., Friday, Bret Edward Buckley, Kabat, Brian, Hu, Leland , Kumthekar, Priya , Anderson, S. Keith , Sarkaria, Jann N. , Ballman, Karla V. , Kizilbash, Sani H. , Sulman, Erik P. , Giannini, Caterina , Piccioni, David Eric , Dixon, Jesse G. , Laack, Nadia N. , Ellingson, Benjamin M. , Galanis, Evanthia

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: 2001-2001

10.1200/jco.2022.40.16_suppl.2001 Get It

2001 Background: PolyADP-ribose polymerase (PARP) is an important modulator of DNA repair following temozolomide (TMZ) therapy. Pre-clinical testing demonstrated significant survival benefit for the combination of TMZ and PARP inhibitor veliparib in a subset of GBM pt-derived xenografts with MGMT promoter hypermethylation. Methods: After central pathology review and MGMT testing, patients (pts) with newly diagnosed, MGMT promoter hypermethylated GBM who had completed concurrent radiation and TMZ were randomized to adjuvant therapy with TMZ (Days 1-5 q28 days) combined with either placebo or veliparib (Days 1-7 q28 days). Veliparib/placebo+TMZ treatment was continued for up to 6 cycles. Pts accrued on the phase II and III portions of the trial were included in the primary endpoint analysis of overall survival (OS), with 90% power to detect a hazard ratio of 0.71 using a one-sided log-rank test with type I error rate of 0.05. The planned phase III sample size was 400 pts with data maturity after 302 deaths. Results: The phase II and III portions of the trial were open to accrual from 12/15/2014 to 2/6/2017 and 11/8/2017 to 10/15/2018, respectively; 447 pts were accrued to the trial and used in this intention to treat analysis. The two treatment groups were well balanced for prognostic factors, 421 pts initiated treatment, median follow-up was 57.8 months (mos), 380 pts had disease progression and 335 pts have died. There was no difference in OS (p = 0.15; HR 0.89 (0.71-1.11), median OS 28.1 vs. 24.8 mo. for TMZ+veliparib vs. TMZ+placebo, respectively) and no difference in secondary endpoint progression free survival (PFS, p = 0.31; HR 1.05 (0.86-1.30), median 13.2 vs. 12.1 mo, respectively). There was a notable trend for extended OS with TMZ+veliparib treatment at intermediate time-points between 24 and 42 mos (3-year OS 36.6% vs. 28.9% with TMZ+placebo, p = 0.09). In an unplanned exploratory analysis, treatment with TMZ at the time of first recurrence was associated with extended post-recurrence OS (p = 0.03) for pts treated on the experimental arm; median post-recurrence OS with TMZ salvage was 17.0 mo in the TMZ+veliparib arm and 12.6 mo in the TMZ+placebo arm, as compared to 9.6 mo in either arm if TMZ salvage was not used. These data are consistent with a possible effect of veliparib limiting the emergence of TMZ resistance in a subset of GBM pts. Conclusions: Veliparib combined with adjuvant TMZ therapy was not associated with significant extension in OS or PFS in newly diagnosed, MGMT hypermethylated GBM pts. However, a subset of pts treated with TMZ+veliparib may have an extended survival following re-treatment with TMZ at first recurrence. Clinical trial information: NCT02152982.
Rapid early progression (REP) of glioblastoma is an independent negative prognostic factor: Results from a systematic review and meta-analysis
Waqar, Mueez , Roncaroli, Federico , Lehrer, Eric J. , D’Urso, Pietro Ivo , Quiñones‐Hinojosa, Alfredo , Trifiletti, Daniel M , Roncaroli, F , Palmer, Joshua D. , Villanueva-Meyer, Javier E. , Braunstein, Steve , Hall, Emma , Aznar, Marianne Camille , Hamer, Philip C. De Witt , Trifiletti, Daniel M. , Wesseling, Pieter , Borst, Gerben R.

Mayo Clinic

Neuro-Oncology Advances | June 4, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac075 | PMID 35769410 Get It

Abstract Background In patients with newly diagnosed glioblastoma, rapid early progression (REP) refers to tumor regrowth between surgery and postoperative chemoradiotherapy. This systematic review and meta-analysis appraised previously published data on REP to better characterize and understand it. Methods Systematic searches of MEDLINE, EMBASE and the Cochrane database from inception to October 21, 2021. Studies describing the incidence of REP—tumor growth between the postoperative MRI scan and pre-radiotherapy MRI scan in newly diagnosed glioblastoma were included. The primary outcome was REP incidence. Results From 1590 search results, 9 studies were included with 716 patients. The median age was 56.9 years (IQR 54.0–58.8 y). There was a male predominance with a median male-to-female ratio of 1.4 (IQR 1.1–1.5). The median number of days between MRI scans was 34 days (IQR 18–45 days). The mean incidence rate of REP was 45.9% (range 19.3%–72.0%) and significantly lower in studies employing functional imaging to define REP (P < .001). REP/non-REP groups were comparable with respect to age (P = .99), gender (P = .33) and time between scans (P = .81). REP was associated with shortened overall survival (HR 1.78, 95% CI 1.30–2.43, P < .001), shortened progression-free survival (HR 1.78, 95% CI 1.30–2.43, P < .001), subtotal resection (OR 6.96, 95% CI 4.51–10.73, P < .001) and IDH wild-type versus mutant tumors (OR 0.20, 95% CI 0.02–0.38, P = .03). MGMT promoter methylation was not associated with REP (OR 1.29, 95% CI 0.72–2.28, P = .39). Conclusions REP occurs in almost half of patients with newly diagnosed glioblastoma and has a strongly negative prognostic effect. Future studies should investigate its biology and effective treatment strategies.
GCT-04. Pattern of Treatment Failures in Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT): A Pooled Analysis of Clinical Trials
Bailey, Shivani , Goldman, Stewart , Khatua, Soumen , Frapaz, Didier, Calaminus, Gabriele , Dhall, Girish , Nicholson, J. W. , Fonseca, Adriana , Faure‐Conter, Cécile , Murray, Matthew J. , Fangusaro, Jason , Nicholson, James, Bouffet, Éric , Bartels, Ute

Mayo Clinic

Neuro-Oncology | June 3, 2022 | Volume: 24 | Issue: Supplement_1 | Pages: i54-i54

10.1093/neuonc/noac079.198 Get It

Abstract BACKGROUND: Central Nervous System- Non-Germinomatous Germ Cell Tumors (CNS-NGGCT) are rare but curable tumors. Due to their rarity, treatment failures remain a poorly characterized disease with unfavorable outcomes. In this study, we sought to characterize the treatment failures in a large cohort of prospectively treated patients. METHODS: European and North American clinical trials for patients with CNS-NGGCT (SIOP-GCT96, SFOP-TGM TC 90/92, COG-ACNS0122 and COG-ACNS1123) were pooled for analysis. Additionally, patients included and treated in the UK and France national registries under strict protocol-guidelines were included as an independent, non-overlapping cohort. RESULTS: A total of 118 patients experienced a treatment failure. Twenty-four patients had progressive disease during therapy and additional eleven patients were diagnosed with growing teratoma syndrome (GTS). Patients with GTS are significantly younger and present with local failures and negative tumor markers. Eighty-three individuals experienced disease relapses after treatment ended. Patients’ metastatic relapses presented significantly earlier than local relapses and were associated with tumor marker elevation (OR: 4.39; p=0.026). In our analysis, focal or whole ventricular (WVI) radiation therapy was not associated with an increased risk of metastatic relapses. CONCLUSIONS: Herein, we present the largest pooled dataset of prospectively treated patients with relapsed CNS-NGGCT. Our study identified younger age and negative tumor markers to be characteristic of GTS. Additionally, we elucidated that metastatic relapses occur earlier than local relapses, are associated with elevated tumor markers, and are not associated with the field of radiation therapy. These findings are of utmost importance for the planning of future clinical trials and the implementation of surveillance strategies in these patients.
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Campo, Elı́as , Jaffe, Elaine S. , Cook, James R. , Quintanilla‐Martínez, Leticia , Brousset, Pierre , Cerroni, Lorenzo , Dirnhofer, Stefan , Friedberg, Jonathan W. , King, Rebecca L., Miguel, Jesús F. San , Seymour, John F. , Advani, Ranjana H. , Ansell, Stephen M. , Au, Wing-Yan, Bergsagel, Leif, Cohen, Jeffrey I. , d’Amore, Francesco, Ghobrial, Irene M. , Kim, Won-Seog, Kumar, Shaji , LaCasce, Ann S. , Laurent, Camille , Lenz, Georg, Leonard, John P. , Link, Michael P., López‐Guillermo, Armando , Mateos, María‐Victoria , Melnick, Ari , Nakamura, Shigeo, Narbaitz, Marina, Pavlovsky, Astrid , Pro, Barbara, Sander, Birgitta , Smith, Sonali M. , Staudt, Louis M. , Thieblemont, Catherine, Tousseyn, Thomas , Wilson, Wyndham H., Yoshino, Tadashi, Dreyling, Martin , Winter, Jane N., Bergsagel, P. Leif , Dirnhofer, S , Bergsagel, P. Leif , Brousset, Pierre , Dogan, Ahmet , Feldman, Andrew L , Ghia, Paolo , Salles, Gilles A , San-Miguel, Jesus , Seymour, John F , Treon, Steven , Vose, Julie , Zucca, Emanuele , Barrionuevo, Carlos , Davies, Andrew , Falini, Brunangelo , Ghobrial, Irene M , Goodlad, John R , Gribben, John G. , Hsi, Eric D , Kahl, Brad S , Kumar, Shaji K , LaCasce, Ann Steward , Mateos, María-Victoria , Macintyre, Elizabeth , Melnick, Ari , Morschhauser, Franck , Pileri, Stefano , Piris, Miguel , Rajkumar, Vincent, Shipp, Margaret Ann , Smith, Sonali M , Zinzani, Pier Luigi , Dreyling, Martin , Scott, David W , Zelenetz, Andrew D , Jaffe, Elaine S , Campo, Elías , Advani, Ranjana H , Quintanilla-Martinez, Leticia , Swerdlow, Steven H. , Anderson, Kenneth C. , Leval, Laurence de , Doǧan, Ahmet , Feldman, Andrew L. , Fend, Falko , Gaulard, Philippe , Ghia, Paolo , Horwitz, Steven M. , Salles, Gilles , Treon, Steven P. , Vose, Julie M. , Zucca, Emanuele , Chan, Wing C., Davies, Andrew , Falini, Brunangelo , Hsi, Eric D. , Kahl, Brad S. , Kim, Won Seog , Lenz, Georg , Macintyre, Elizabeth , Morschhauser, Franck , Pileri, Stefano , Piris, Miguel Á. , Rajkumar, S. Vincent , Rosen, Steven T. , Sehn, Laurie H. , Thiéblemont, Catherine , Wilson, Wyndham H. , Yoshino, Tadashi, Zinzani, Pier Luigi , Scott, David W. , Winter, Jane N. , Zelenetz, Andrew D.

Mayo Clinic

Blood | June 2, 2022 | Volume: 140 | Issue: 11 | Pages: 1229-1253

10.1182/blood.2022015851 | PMID 35653592 Get It

Abstract Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.
Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020
Sauer, Adam , Daher, Ghazal S. , Lohse, Christine M. , Glasgow, Amy E. , Douse, Dontre’ M. , Moore, Eric J. , Ighodaro, Eseosa T. , Abel, Kathryn M. Van , Glasgow, Amy E. , Sauer, Adam B, Van Abel, Kathryn M , Glasgow, Amy E , Habermann, Elizabeth B. , Yin, Linda X.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | June 2, 2022 | Volume: 148 | Issue: 7 | Pages: 662

10.1001/jamaoto.2022.1028 | PMID 35653143 Get It

Age and weight considerations for the use of continuous positive airway pressure therapy in pediatric populations: an American Academy of Sleep Medicine position statement
Amos, Louella, Afolabi‐Brown, Olufunke , Gault, Dominic, Lloyd, Robin M. , Prero, Moshe , Rosen, Carol L. , Malhotra, Raman K. , Ramar, Kannan , Rowley, James A. , Abbasi-Feinberg, Fariha, Aurora, R. Nisha , Kazmi, Uzma, Kuhlmann, David, Olson, Eric J. , Shelgikar, Anita V., Thomas, Sherene M., Trotti, Lynn Marie , Lloyd, Robin, Trotti, Lynn Marie , Martin, Jennifer L. , Kapur, Vishesh K. , Kazmi, Uzma

Mayo Clinic

Journal of Clinical Sleep Medicine | June 1, 2022 | Volume: 18 | Issue: 8 | Pages: 2041-2043

10.5664/jcsm.10098 | PMID 35638127 Get It

Unifying theory of carotid plaque disruption based on structural phenotypes and forces expressed at the lumen/wall interface
Mousavi, H A Ebrahimzadeh, Liu, Yang , Khalsa, Siri Sahib S. , Reddy, Adithya , Brinjikji, Waleed , Bhambri, Ankur, Cockrum, Joshua , Thompson, B. Gregory , Seibel, Eric J. , Yonas, Howard, Savastano, Luis , Liu, Yang , Zheng, Yihao , Mousavi, Hossein, Davis, Evan, Pandey, Aditya S , Gordon, David J.

Mayo Clinic

Stroke and Vascular Neurology | June 1, 2022 | Volume: 7 | Issue: 6 | Pages: 465-475

10.1136/svn-2021-001451 | PMID 35649687 Get It

Objectives To integrate morphological, haemodynamic and mechanical analysis of carotid atheroma driving plaque disruption. Materials and methods First, we analysed the phenotypes of carotid endarterectomy specimens in a photographic dataset A, and matched them with the likelihood of preoperative stroke. Second, laser angioscopy was used to further define the phenotypes in intact specimens (dataset B) and benchmark with histology. Third, representative vascular geometries for each structural phenotype were analysed with Computational Fluid Dynamics (CFD), and the mechanical strength of the complicated atheroma to resist penetrating forces was quantified (n=14). Results In dataset A (n=345), ulceration (fibrous cap disruption) was observed in 82% of all plaques, intraplaque haemorrhage in 68% (93% subjacent to an ulcer) and false luminal formation in 48%. At least one of these ‘rupture’ phenotypes was found in 97% of symptomatic patients (n=69) compared with 61% in asymptomatic patients. In dataset B (n=30), laser angioscopy redemonstrated the structural phenotypes with near-perfect agreement with histology. In CFD, haemodynamic stress showed a large pulse magnitude, highest upstream to the point of maximal stenosis and on ulceration the inflow stream excavates the necrotic core cranially and then recirculates into the true lumen. Based on mechanical testing (n=14), the necrotic core is mechanically weak and penetrated by the blood on fibrous cap disruption. Conclusions Fibrous cap ulceration, plaque haemorrhage and excavation are sequential phenotypes of plaque disruption resulting from the chiselling effect of haemodynamic forces over unmatched mechanical tissue strength. This chain of events may result in thromboembolic events independently of the degree of stenosis.
Retrospective Review of Surgical Site Infections after Endoscopic Endonasal Sellar and Parasellar Surgery: Multicenter Quality Data from the North American Skull Base Society
Saleh, Sara , Sullivan, Stephen E., Roxbury, Christopher R. , Das, Paramita , Hachem, Ralph Abi , Ackall, Feras , Jang, David W. , Çeltikçi, Emrah , Şahin, Muammer Melih , D’Souza, Glen , Evans, James J., Nyquist, Gurston , Khalafallah, Adham M. , Mukherjee, Debraj , Camp, Samantha, Ghiam, Michael K. , Levine, Corinna G. , Field, Melvin , Adappa, Nithin D. , Rassekh, Christopher H. , Sweis, Auddie M. , Wilson, Meghan, Patel, Shivam , Gardner, Paul A. , Glancz, Laurence , Bagchi, Ananyo , Dow, Graham, Robertson, Iain, Rangarajan, Sanjeet V., Celtikci, Emrah , Mukherjee, Debraj , Rowan, Nicholas R , Van Gompel, Jamie J , Goyal, Neerav , Saleh, Sara , Bellile, Emily Light , Rowan, Nicholas R. , Camp, Samantha , Choby, Garret , Gompel, Jamie J. Van , Adappa, Nithin D. , Locke, Tran B. , Zacharia, Brad E. , Snyderman, Carl H , Wang, Eric W , Michael, Lattimore Madison , McKean, Erin L.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | June 1, 2022 | Volume: 83 | Issue: 06 | Pages: 579-588

10.1055/a-1865-3202 | PMID 36393885 Get It

Abstract Introduction Transnasal access to the anterior skull base provides a minimally invasive approach for sellar and parasellar masses compared with its open counterparts. The unique microbiome of the sinonasal mucosa provides distinct challenges not encountered with other cranial approaches. The use of antibiotics in these cases has not been standardized, and data remain scarce regarding infectious outcomes. Methods We conducted a multicenter retrospective analysis of shared quality data points for the endoscopic endonasal approach (EEA) for pituitary adenomas, along with other sellar and parasellar region masses that were included by participating institutions. Patient and operative characteristics, perioperative and postoperative antibiotic regimens and their durations, intraoperative and postoperative cerebrospinal fluid leak, and onset of postoperative meningitis and sinusitis were compared. Results Fifteen institutions participated and provided 6 consecutive months' worth of case data. Five hundred ninety-three cases were included in the study, of which 564 were pituitary adenomectomies. The incidences of postoperative meningitis and sinusitis were low (0.67 and 2.87% for all pathologies, respectively; 0.35% meningitis for pituitary adenomas) and did not correlate with any specific antibiotic regimen. Immunocompromised status posed an increased odds of meningitis in pituitary adenomectomies (28.6, 95% confidence interval [1.72–474.4]). Conclusions The results show no clear benefit to postoperative antimicrobial use in EEA, with further larger studies needed.